Patient-Reported Outcomes in OlympiA : A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer
PURPOSE: The OlympiA randomized phase III trial compared 1 year of olaparib (OL) or placebo (PL) as adjuvant therapy in patients with germline BRCA1/2, high-risk human epidermal growth factor receptor 2-negative early breast cancer after completing (neo)adjuvant chemotherapy ([N]ACT), surgery, and radiotherapy. The patient-reported outcome primary hypothesis was that OL-treated patients may experience greater fatigue during treatment.
METHODS: Data were collected before random assignment, and at 6, 12, 18, and 24 months. The primary end point was fatigue, measured with the Functional Assessment of Chronic Illness Therapy-Fatigue scale. Secondary end points, assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Core 30 item, included nausea and vomiting (NV), diarrhea, and multiple functional domains. Scores were compared between treatment groups using mixed model for repeated measures. Two-sided P values <.05 were statistically significant for the primary end point. All secondary end points were descriptive.
RESULTS: One thousand five hundred and thirty-eight patients (NACT: 746, ACT: 792) contributed to the analysis. Fatigue severity was statistically significantly greater for OL versus PL, but not clinically meaningfully different by prespecified criteria (≥3 points) at 6 months (diff OL v PL: NACT: -1.3 [95% CI, -2.4 to -0.2]; P = .022; ACT: -1.3 [95% CI, -2.3 to -0.2]; P = .017) and 12 months (NACT: -1.6 [95% CI, -2.8 to -0.3]; P = .017; ACT: -1.3 [95% CI, -2.4 to -0.2]; P = .025). There were no significant differences in fatigue severity between treatment groups at 18 and 24 months. NV severity was worse in patients treated with OL compared with PL at 6 months (NACT: 6.0 [95% CI, 4.1 to 8.0]; ACT: 5.3 [95% CI, 3.4 to 7.2]) and 12 months (NACT: 6.4 [95% CI, 4.4 to 8.3]; ACT: 4.5 [95% CI, 2.8 to 6.1]). During treatment, there were some clinically meaningful differences between groups for other symptoms but not for function subscales or global health status.
CONCLUSION: Treatment-emergent symptoms from OL were limited, generally resolving after treatment ended. OL- and PL-treated patients had similar functional scores, slowly improving during the 24 months after (N)ACT and there was no clinically meaningful persistence of fatigue severity in OL-treated patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 42(2024), 11 vom: 10. Apr., Seite 1288-1300 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 10.04.2024 published: Print-Electronic ClinicalTrials.gov: NCT02032823 Citation Status MEDLINE |
|---|
| doi: |
10.1200/JCO.23.01214 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367905590 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367905590 | ||
| 003 | DE-627 | ||
| 005 | 20240410232448.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240202s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.23.01214 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM367905590 | ||
| 035 | |a (NLM)38301187 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ganz, Patricia A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Patient-Reported Outcomes in OlympiA |b A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT02032823 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: The OlympiA randomized phase III trial compared 1 year of olaparib (OL) or placebo (PL) as adjuvant therapy in patients with germline BRCA1/2, high-risk human epidermal growth factor receptor 2-negative early breast cancer after completing (neo)adjuvant chemotherapy ([N]ACT), surgery, and radiotherapy. The patient-reported outcome primary hypothesis was that OL-treated patients may experience greater fatigue during treatment | ||
| 520 | |a METHODS: Data were collected before random assignment, and at 6, 12, 18, and 24 months. The primary end point was fatigue, measured with the Functional Assessment of Chronic Illness Therapy-Fatigue scale. Secondary end points, assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Core 30 item, included nausea and vomiting (NV), diarrhea, and multiple functional domains. Scores were compared between treatment groups using mixed model for repeated measures. Two-sided P values <.05 were statistically significant for the primary end point. All secondary end points were descriptive | ||
| 520 | |a RESULTS: One thousand five hundred and thirty-eight patients (NACT: 746, ACT: 792) contributed to the analysis. Fatigue severity was statistically significantly greater for OL versus PL, but not clinically meaningfully different by prespecified criteria (≥3 points) at 6 months (diff OL v PL: NACT: -1.3 [95% CI, -2.4 to -0.2]; P = .022; ACT: -1.3 [95% CI, -2.3 to -0.2]; P = .017) and 12 months (NACT: -1.6 [95% CI, -2.8 to -0.3]; P = .017; ACT: -1.3 [95% CI, -2.4 to -0.2]; P = .025). There were no significant differences in fatigue severity between treatment groups at 18 and 24 months. NV severity was worse in patients treated with OL compared with PL at 6 months (NACT: 6.0 [95% CI, 4.1 to 8.0]; ACT: 5.3 [95% CI, 3.4 to 7.2]) and 12 months (NACT: 6.4 [95% CI, 4.4 to 8.3]; ACT: 4.5 [95% CI, 2.8 to 6.1]). During treatment, there were some clinically meaningful differences between groups for other symptoms but not for function subscales or global health status | ||
| 520 | |a CONCLUSION: Treatment-emergent symptoms from OL were limited, generally resolving after treatment ended. OL- and PL-treated patients had similar functional scores, slowly improving during the 24 months after (N)ACT and there was no clinically meaningful persistence of fatigue severity in OL-treated patients | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a BRCA1 Protein |2 NLM | |
| 650 | 7 | |a BRCA1 protein, human |2 NLM | |
| 650 | 7 | |a BRCA2 Protein |2 NLM | |
| 650 | 7 | |a BRCA2 protein, human |2 NLM | |
| 650 | 7 | |a ERBB2 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a olaparib |2 NLM | |
| 650 | 7 | |a WOH1JD9AR8 |2 NLM | |
| 650 | 7 | |a Phthalazines |2 NLM | |
| 650 | 7 | |a Piperazines |2 NLM | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Bandos, Hanna |e verfasserin |4 aut | |
| 700 | 1 | |a Španić, Tanja |e verfasserin |4 aut | |
| 700 | 1 | |a Friedman, Sue |e verfasserin |4 aut | |
| 700 | 1 | |a Müller, Volkmar |e verfasserin |4 aut | |
| 700 | 1 | |a Kuemmel, Sherko |e verfasserin |4 aut | |
| 700 | 1 | |a Delaloge, Suzette |e verfasserin |4 aut | |
| 700 | 1 | |a Brain, Etienne |e verfasserin |4 aut | |
| 700 | 1 | |a Toi, Masakazu |e verfasserin |4 aut | |
| 700 | 1 | |a Yamauchi, Hideko |e verfasserin |4 aut | |
| 700 | 1 | |a de Dueñas, Eduardo-M |e verfasserin |4 aut | |
| 700 | 1 | |a Armstrong, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Im, Seock-Ah |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Chuan-Gui |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Sarosiek, Tomasz |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Priyanka |e verfasserin |4 aut | |
| 700 | 1 | |a Geng, Cuizhi |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Peifen |e verfasserin |4 aut | |
| 700 | 1 | |a Rhiem, Kerstin |e verfasserin |4 aut | |
| 700 | 1 | |a Frauchiger-Heuer, Heike |e verfasserin |4 aut | |
| 700 | 1 | |a Wimberger, Pauline |e verfasserin |4 aut | |
| 700 | 1 | |a t'Kint de Roodenbeke, Daphné |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Ning |e verfasserin |4 aut | |
| 700 | 1 | |a Goodwin, Annabel |e verfasserin |4 aut | |
| 700 | 1 | |a Chakiba-Brugère, Camille |e verfasserin |4 aut | |
| 700 | 1 | |a Friedlander, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Keun Seok |e verfasserin |4 aut | |
| 700 | 1 | |a Giacchetti, Sylvie |e verfasserin |4 aut | |
| 700 | 1 | |a Takano, Toshimi |e verfasserin |4 aut | |
| 700 | 1 | |a Henao-Carrasco, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Virani, Shamsuddin |e verfasserin |4 aut | |
| 700 | 1 | |a Valdes-Albini, Frances |e verfasserin |4 aut | |
| 700 | 1 | |a Domchek, Susan M |e verfasserin |4 aut | |
| 700 | 1 | |a Bane, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a McCarron, Edward C |e verfasserin |4 aut | |
| 700 | 1 | |a Mita, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Rossi, Giovanna |e verfasserin |4 aut | |
| 700 | 1 | |a Rastogi, Priya |e verfasserin |4 aut | |
| 700 | 1 | |a Fielding, Anitra |e verfasserin |4 aut | |
| 700 | 1 | |a Gelber, Richard D |e verfasserin |4 aut | |
| 700 | 1 | |a Scheepers, Elsemieke D |e verfasserin |4 aut | |
| 700 | 1 | |a Cameron, David |e verfasserin |4 aut | |
| 700 | 1 | |a Garber, Judy |e verfasserin |4 aut | |
| 700 | 1 | |a Geyer, Charles E |e verfasserin |4 aut | |
| 700 | 1 | |a Tutt, Andrew N J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology : official journal of the American Society of Clinical Oncology |d 1986 |g 42(2024), 11 vom: 10. Apr., Seite 1288-1300 |w (DE-627)NLM012608777 |x 1527-7755 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:11 |g day:10 |g month:04 |g pages:1288-1300 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.23.01214 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2024 |e 11 |b 10 |c 04 |h 1288-1300 | ||